Mohanty, Salini
Podmore, Bélène
Cuñado Moral, Ana
Weiss, Thomas
Matthews, Ian
Sarpong, Eric
Méndez, Ignacio
Qizilbash, Nawab
Funding for this research was provided by:
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Article History
Received: 6 September 2022
Accepted: 3 January 2023
First Online: 30 January 2023
Declarations
:
: The Clinical Practice Research Datalink (CPRD) is an ongoing primary care database of anonymized medical records from general practitioners, with coverage of over 19 million patients from 937 practices in the UK. All methods were performed in accordance with the relevant guidelines and regulations. Protocol approval was received from the CPRD Independent Scientific Advisory Committee (ISAC), the ISAC number was 20_000260. Informed consent was not required for conducting this study, as the CPRD database provides anonymized data from medical records, so it is not possible to identify patients from GP practice in CPRD database.
: Not applicable.
: This research was sponsored and funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. BP, AC, IMe and NQ are employees of OXON Epidemiology Ltd., Epidemiology & Statistics, Madrid, Spain, an independent contract research organization, that received funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA to design and conduct this study. SM, IMa, ES and TW are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock/stock options in Merck & Co., Inc., Rahway, NJ, USA.